Literature DB >> 22054423

Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.

John M Akudugu1, Roger W Howell.   

Abstract

PURPOSE: Although the distribution of therapeutic agents within cell populations may appear uniform at the macroscopic level, the distribution at the multicellular level is nonuniform. As such, the mean agent concentration in tissue may not be a suitable quantity for use in predicting biological effects. Failure in chemotherapy and targeted radionuclide therapy has been attributed, in part, to the ubiquity of lognormal distributions of therapeutic agents. To improve capacity to predict biological response, this work develops approaches that determine the fate of a cell population on a cell-by-cell basis.
METHODS: Incorporation of the α-particle emitting radiochemical ((210)Po-citrate) and two anticancer drugs (daunomycin and doxorubicin) by Chinese hamster V79 cells was determined using flow cytometry. Monte Carlo simulation was used to estimate cell survival on the bases of mean and individual cell incorporation of each cytotoxic agent. The interrelationships between the Monte Carlo simulated cell survival and clonogenic cell survival were evaluated.
RESULTS: Cell survival obtained by Monte Carlo simulation based on individual cell incorporation was in good agreement with clonogenic cell survival for all agents. However, the agreement was poor when the simulation was carried out using the mean cell incorporation of the agents.
CONCLUSION: These data indicate that, with the aid of flow cytometry, Monte Carlo simulations can be used to predict the toxicity of therapeutic agents in a manner that takes into account the effects of lognormal and other nonuniform distributions of agents within cell populations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22054423      PMCID: PMC4029157          DOI: 10.3109/09553002.2012.638357

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  36 in total

1.  Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei.

Authors:  Y Kvinnsland; T Stokke; E Aurlien
Journal:  Radiat Res       Date:  2001-02       Impact factor: 2.841

Review 2.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails.

Authors:  John M Akudugu; Prasad V S V Neti; Roger W Howell
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

4.  Lognormal distribution of cellular uptake of radioactivity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaffolds.

Authors:  Didier Rajon; Wesley E Bolch; Roger W Howell
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

5.  Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.

Authors:  Danny L Costantini; Daniela F Villani; Katherine A Vallis; Raymond M Reilly
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

6.  Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Authors:  Yelena V Kovtun; Charlene A Audette; Michele F Mayo; Gregory E Jones; Heather Doherty; Erin K Maloney; Hans K Erickson; Xiuxia Sun; Sharon Wilhelm; Olga Ab; Katharine C Lai; Wayne C Widdison; Brenda Kellogg; Holly Johnson; Jan Pinkas; Robert J Lutz; Rajeeva Singh; Victor S Goldmacher; Ravi V J Chari
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

Review 7.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.

Authors:  M Gerlinger; C Swanton
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

Review 8.  Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

9.  Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study.

Authors:  Sonia Aroui; Souhir Brahim; Michel De Waard; Abderraouf Kenani
Journal:  Biochem Biophys Res Commun       Date:  2009-11-13       Impact factor: 3.575

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more
  2 in total

1.  A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Authors:  John M Akudugu; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-04-14       Impact factor: 2.408

2.  Survival of tumor and normal cells upon targeting with electron-emitting radionuclides.

Authors:  Didier Rajon; Wesley E Bolch; Roger W Howell
Journal:  Med Phys       Date:  2013-01       Impact factor: 4.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.